AR056092A1 - Tratamiento de inflamaciones y anomalias vasculares oftalmologicas - Google Patents
Tratamiento de inflamaciones y anomalias vasculares oftalmologicasInfo
- Publication number
- AR056092A1 AR056092A1 ARP060104210A ARP060104210A AR056092A1 AR 056092 A1 AR056092 A1 AR 056092A1 AR P060104210 A ARP060104210 A AR P060104210A AR P060104210 A ARP060104210 A AR P060104210A AR 056092 A1 AR056092 A1 AR 056092A1
- Authority
- AR
- Argentina
- Prior art keywords
- bodies
- patient
- apoptotic
- treatment
- glycerol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Tratamiento de inflamaciones y anomalías vasculares del ojo, incluyendo las que están relacionadas con una isquemia, su profilaxis y alivio de las mismas, por administracion al mamífero de pequenas cantidades de cuerpos que presentan grupos de glicerol-fosfato, tales como liposomas de fosfatidilglicerol. Reivindicacion 1: Un proceso para demorar el desarrollo y/o avance de un trastorno inflamatorio y/o vascular en el ojo de un paciente mamífero, caracterizado porque comprende administrar al paciente una cantidad eficaz de cuerpos aceptables para uso farmacéutico que presentan grupos de glicerol-fosfato, que son de un tamano parecido al de células apoptoticas o cuerpos apoptoticos. Reivindicacion 13: Uso, caracterizado porque es para la preparacion o elaboracion de un medicamento, para el tratamiento o la profilaxis de un trastorno inflamatorio y/o vascular en el ojo de un paciente mamífero, de cuerpos aceptables para uso farmacéutico que presentan grupos de glicerol- fosfato, de un tamano semejante al tamano de células apoptoticas o cuerpos apoptoticos. Reivindicacion 25: Un método de tratamiento del componente de edema macular diabético de la retinopatía diabética en un paciente humano, caracterizado porque dicho método comprende identificar un paciente humano que presenta edema macular diabético como componente de una retinopatía diabética, y administrarle al paciente una cantidad eficaz de cuerpos aceptables para uso farmacéutico que presentan grupos de glicerol-fosfato, de un tamano semejante al de células apoptoticas o cuerpos apoptoticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72100905P | 2005-09-26 | 2005-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056092A1 true AR056092A1 (es) | 2007-09-19 |
Family
ID=37712817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104210A AR056092A1 (es) | 2005-09-26 | 2006-09-26 | Tratamiento de inflamaciones y anomalias vasculares oftalmologicas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070071805A1 (es) |
| EP (1) | EP1928420A1 (es) |
| JP (1) | JP2009510076A (es) |
| AR (1) | AR056092A1 (es) |
| AU (1) | AU2006294756A1 (es) |
| CA (1) | CA2622475A1 (es) |
| TW (1) | TW200803919A (es) |
| WO (1) | WO2007038549A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007096744A1 (en) * | 2006-02-21 | 2007-08-30 | Pfizer Products Inc. | Methods for the treatment of macular degeneration and related eye conditions |
| US20090105245A1 (en) * | 2006-12-21 | 2009-04-23 | Bingaman David P | Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor |
| WO2012126965A1 (en) * | 2011-03-21 | 2012-09-27 | Gregor Cevc | Drug-free compositions and methods for diminishing peripheral inflammation and pain |
| WO2017184081A1 (en) * | 2016-04-19 | 2017-10-26 | Nanyang Technological University | Subconjuctival depot forming formulations for ocular drug delivery |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU633078B2 (en) * | 1989-04-04 | 1993-01-21 | Alcon Laboratories, Inc. | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions |
| DE10141018A1 (de) * | 2001-08-22 | 2003-03-13 | Eth Zuerich Eidgenoessische Te | Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges |
| CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
-
2006
- 2006-09-25 CA CA002622475A patent/CA2622475A1/en not_active Abandoned
- 2006-09-25 US US11/527,299 patent/US20070071805A1/en not_active Abandoned
- 2006-09-25 AU AU2006294756A patent/AU2006294756A1/en not_active Abandoned
- 2006-09-25 EP EP06815506A patent/EP1928420A1/en not_active Withdrawn
- 2006-09-25 TW TW095135375A patent/TW200803919A/zh unknown
- 2006-09-25 JP JP2008533538A patent/JP2009510076A/ja active Pending
- 2006-09-25 WO PCT/US2006/037556 patent/WO2007038549A1/en active Application Filing
- 2006-09-26 AR ARP060104210A patent/AR056092A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007038549A1 (en) | 2007-04-05 |
| US20070071805A1 (en) | 2007-03-29 |
| CA2622475A1 (en) | 2007-04-05 |
| EP1928420A1 (en) | 2008-06-11 |
| WO2007038549B1 (en) | 2007-07-12 |
| JP2009510076A (ja) | 2009-03-12 |
| AU2006294756A1 (en) | 2007-04-05 |
| TW200803919A (en) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BR112017014332A2 (pt) | métodos de tratamento de doenças retinianas | |
| MX2012005816A (es) | Uso de prostaglandinas f2alfa y analogos para la curacion de lesiones de cornea y conjuntiva. | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| Griffith et al. | Treatment of corneal chemical alkali burns with a crosslinked thiolated hyaluronic acid film | |
| JP2019070055A (ja) | ドライアイ治療用点眼剤 | |
| De Monchy et al. | Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): a case report | |
| AR056092A1 (es) | Tratamiento de inflamaciones y anomalias vasculares oftalmologicas | |
| CA2897518C (fr) | Composition dermatologique topique comportant un peptide antimicrobien cationique couple a un lipide et de l'acide hyaluronique. | |
| WO2011137344A3 (en) | Anti-s1p antibody treatment of patients with ocular disease | |
| BR112022015579A2 (pt) | Composições para tratamento de doenças oculares | |
| Jung et al. | Clinical efficacy of topical 3% diquafosol tetrasodium in short tear film break-up time dry eye | |
| Xu et al. | Frequency of retinal macroaneurysms in adult Chinese: the Beijing Eye Study | |
| Kaldırım et al. | Efficacy of hyperbaric oxygen therapy on central corneal thickness, intraocular pressure, and nerve fiber layer in patients with type 2 diabetes: A prospective cohort study | |
| RU2662364C2 (ru) | Способ лечения катаракты и глазные капли для его осуществления | |
| RU2542799C1 (ru) | Способ лечения кератоконуса роговицы | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| RU2559580C1 (ru) | Препарат для лечения синдрома "сухого глаза" | |
| RU2644701C1 (ru) | Способ консервативного лечения адаптированных проникающих ранений роговицы | |
| Marchegiani et al. | Riboflavin/UV-A corneal phototherapy as stand-alone management of ulcerative keratitis in dogs | |
| Sato et al. | Relative potency of tyrosol in the treatment of endotoxin-induced uveitis in rats | |
| Ayaki et al. | Effect of ophthalmic solution components on acrylic intraocular lenses | |
| ES2276906T3 (es) | Solucion oftalmica que contiene carboxi metilo beta-1,3 glucano. | |
| Terada et al. | The anti-inflammatory effect of 0.1% bromfenac and 0.1% betamethasone combination in post-cataract surgery patients with diabetes mellitus | |
| RU2575590C1 (ru) | Способ лечения рецидивирующих эрозий роговицы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |